August 16, 2025Open Access

Circulating SDF4 as a Potential Early Detection Biomarker for Pancreatic Cancer

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Case-control study reports elevated SDF4 levels in pancreatic cancer patients, suggesting its potential as a biomarker for early detection.

SDF4 levels are significantly elevated in pancreatic cancer patients, indicating its potential role as a biomarker.
In a study of 124 pancreatic cancer patients, SDF4 showed an AUC of 0.82, demonstrating promising diagnostic performance.
Plasma SDF4 concentrations were measured using enzyme-linked immunosorbent assay, a reliable testing method.
Further validation of SDF4 in prospective cohorts is necessary to clarify its clinical utility in combination with other biomarkers.

Kageyama et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Case-control study reports elevated SDF4 levels in pancreatic cancer patients, suggesting its potential as a biomarker for early detection.